stockrowXeris Biopharma Holdings, Inc.
XERS Healthcare Drug Manufacturers Specialty & Generic
Xeris Biopharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $291.8 million, up 43.7% from fiscal 2024.
- Revenue
- +44.2%
- EPS
- +1,479.0%
- Free cash flow
- +93.2%
- Total debt
- −13.6%
Quarter to September 2026, against a year earlier
Follow XERS
Alert me
Xeris Biopharma Holdings, Inc. (XERS) Operating margin
Xeris Biopharma Holdings, Inc.'s operating margin over the twelve months to 30 September 2026 was 12.7%, up 4.2 percentage points from fiscal 2025 (8.53%). Over the past ten years it has ranged from −4,496.0% (fiscal 2019) to 8.53% (fiscal 2025) — the current reading is the highest in ten years. That is above the Drug Manufacturers Specialty & Generic industry median of 0.00% and above the Healthcare sector median of 0.00%.
Operating margin, annual
Embed this chart
Annual newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| FY2025 | 8.53% | 25.10 |
| FY2024 | −16.6% | 10.28 |
| FY2023 | −26.9% | 47.47 |
| FY2022 | −74.3% | 157.90 |
| FY2021 | −232.2% | 176.62 |
| FY2020 | −408.8% | 4,087.12 |
| FY2019 | −4,496.0% | (2,046.76) |
| FY2018 | −2,449.2% | (737.82) |
| FY2017 | −1,711.4% | (480.59) |
| FY2016 | −1,230.8% | — |
Quarterly newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| Sep 2026 | 15.8% | 10.16 |
| Jun 2026 | 5.62% | (3.90) |
| Mar 2026 | 9.52% | (10.03) |
| Dec 2025 | 19.6% | 10.50 |
| 33 more quarters | Free account |
Against its own ten years
Operating margin against peers
| Company | Operating margin |
|---|---|
| PBH Prestige Consumer Healthcare Inc. compare | 25.0% |
| XERS Xeris Biopharma Holdings, Inc. | 12.7% |
| AMLX Amylyx Pharmaceuticals, Inc. compare | 0.00% |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 0.00% |
| TRLV Trulieve Cannabis Corp. compare | 0.00% |
| BCRX BioCryst Pharmaceuticals, Inc. compare | −30.1% |
| PRGO Perrigo Company plc compare | −39.4% |
| ALVO Alvotech compare | −42.4% |
| RGC Regencell Bioscience Holdings Limited compare | — |
| Drug Manufacturers Specialty & Generic industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Operating margin is
EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.
EBIT ÷ Revenue
More on XERS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement